Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;41(Database issue):D338-43.
doi: 10.1093/nar/gks936. Epub 2012 Oct 22.

ValidNESs: a database of validated leucine-rich nuclear export signals

Affiliations

ValidNESs: a database of validated leucine-rich nuclear export signals

Szu-Chin Fu et al. Nucleic Acids Res. 2013 Jan.

Abstract

ValidNESs (http://validness.ym.edu.tw/) is a new database for experimentally validated leucine-rich nuclear export signal (NES)-containing proteins. The therapeutic potential of the chromosomal region maintenance 1 (CRM1)-mediated nuclear export pathway and disease relevance of its cargo proteins has gained recognition in recent years. Unfortunately, only about one-third of known CRM1 cargo proteins are accessible in a single database since the last compilation in 2003. CRM1 cargo proteins are often recognized by a classical NES (leucine-rich NES), but this signal is notoriously difficult to predict from sequence alone. Fortunately, a recently developed prediction method, NESsential, is able to identify good candidates in some cases, enabling valuable hints to be gained by in silico prediction, but until now it has not been available through a web interface. We present ValidNESs, an integrated, up-to-date database holding 221 NES-containing proteins, combined with a web interface to prediction by NESsential.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pie chart of species. Distribution of entries in ValidNESs. The number of species in which NES-containing proteins were validated are indicated in parenthesis.
Figure 2.
Figure 2.
Sequence logos for NES sites. Sequence logos generated by the WebLogo server for NES motif matches after removing redundant sequences (with sequence identity >25%) and aligning the three hydrophobic positions within the motif. In general, the preference for negatively charged residues is lower than previously observed in NESbase. (A) Sequence logo for 6-mer NES motif matches with upstream and downstream 10-mer flanks (227 sites). (B) Sequence logo for 7-mer NES motif matches with upstream and downstream 10-mer flanks (162 sites).
Figure 3.
Figure 3.
An overview of the search and search result interfaces in ValidNESs. ValidNESs stores metadata in two tables and provides three search functions to access these data. Once users submit their queries, the search result in text file format and FASTA format (for table of NES-containing proteins only) is generated for download. Meanwhile, ValidNESs also displays an online table for quick browsing.

Similar articles

Cited by

References

    1. Bogerd HP, Fridell RA, Benson RE, Hua J, Cullen BR. Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol. Cell. Biol. 1996;16:4207–4214. - PMC - PubMed
    1. Kosugi S, Hasebe M, Tomita M, Yanagawa H. Nuclear export signal consensus sequences defined using a localization-based yeast selection system. Traffic. 2008;9:2053–2062. - PubMed
    1. Fu S-C, Imai K, Horton P. Prediction of leucine-rich nuclear export signal containing proteins with NESsential. Nucleic Acids Res. 2011;39:e111. - PMC - PubMed
    1. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr. Med. Chem. 2008;15:2648–2655. - PubMed
    1. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int. J. Cancer. 2009;124:1829–1840. - PMC - PubMed

Publication types